SCHEMBL30765871

SCHEMBL30765871

C[C@@H](Nc1cnc(OC2CC2)n(CC(=O)NCc2cc3cnccc3[nH]2)c1=O)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 2/20 0.36
MAPK1 P28482 3/20 0.35
USP2 O75604 2/20 0.33
NAMPT P43490 5/20 0.32
ALDH1A1 P00352 3/20 0.32
KDM4E B2RXH2 3/20 0.32
NPSR1 Q6W5P4 2/20 0.32
HCRTR1 O43613 1/20 0.32
GAA P10253 1/20 0.32
TSHR P16473 1/20 0.32
MASP2 O00187 1/20 0.32
IDH1 O75874 1/20 0.32
MAPT P10636 2/20 0.31
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
KMT2A Q03164 1/20 0.31
CTDSP1 Q9GZU7 1/20 0.31
HSD17B10 Q99714 2/20 0.31
F3 P13726 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765625 0.92 F2 (0.36) F2MAPK1USP2ALDH1A1KDM4E
SCHEMBL30765642 0.88 MAPK1 (0.35) F2MAPK1USP2NAMPTALDH1A1
SCHEMBL30765885 0.87 MAPK1 (0.34) F2MAPK1USP2NAMPTALDH1A1
SCHEMBL31558497 0.87 F2 (0.35) F2MAPK1USP2NAMPTALDH1A1
SCHEMBL30765646 0.87 MAPK1 (0.38) F2MAPK1USP2NAMPTALDH1A1
SCHEMBL30765543 0.87 ELANE (0.39) F2MAPK1F3
SCHEMBL30765806 0.86 MAPK1 (0.36) F2MAPK1USP2NAMPTALDH1A1
SCHEMBL30765516 0.86 NTRK1 (0.35) F2MAPK1USP2ALDH1A1KDM4E
SCHEMBL30766011 0.85 CMA1 (0.33) F2MAPK1USP2ALDH1A1KDM4E
SCHEMBL30766124 0.85 F2 (0.36) F2MAPK1NAMPTMASP2IDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed